{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:50:34Z","timestamp":1788918634254,"version":"build-2803163510"},"reference-count":120,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Non-small-cell lung cancer (NSCLC) afflicts about 2 million people worldwide, with both genetic (familial) and environmental factors contributing to its development and spread. The inadequacy of currently available therapeutic techniques, such as surgery, chemotherapy, and radiation therapy, in addressing NSCLC is reflected in the very low survival rate of this disease. Therefore, newer approaches and combination therapy regimens are required to reverse this dismal scenario. Direct administration of inhalable nanotherapeutic agents to the cancer sites can potentially lead to optimal drug use, negligible side effects, and high therapeutic gain. Lipid-based nanoparticles are ideal agents for inhalable delivery owing to their high drug loading, ideal physical traits, sustained drug release, and biocompatibility. Drugs loaded within several lipid-based nanoformulations, such as liposomes, solid-lipid nanoparticles, lipid-based micelles, etc., have been developed as both aqueous dispersed formulations as well as dry-powder formulations for inhalable delivery in NSCLC models in vitro and in vivo. This review chronicles such developments and charts the future prospects of such nanoformulations in the treatment of NSCLC.<\/jats:p>","DOI":"10.3390\/pharmaceutics15051457","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T01:37:09Z","timestamp":1683769029000},"page":"1457","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Lipid-Based Inhalable Micro- and Nanocarriers of Active Agents for Treating Non-Small-Cell Lung Cancer"],"prefix":"10.3390","volume":"15","author":[{"given":"Sona","family":"Gandhi","sequence":"first","affiliation":[{"name":"Department of Chemistry, School of Basic & Applied Sciences, Galgotias University, Greater Noida 203201, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrajit","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Delhi, Delhi 110007, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung Cancer 2020 Epidemiology, Etiology, and Prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin. Chest Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.mcna.2018.12.006","article-title":"Lung Cancer","volume":"103","author":"Nasim","year":"2019","journal-title":"Med. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1164\/rccm.200502-235PP","article-title":"Familial Lung Cancer Genetic Susceptibility and Relationship to Chronic Obstructive Pulmonary Disease","volume":"173","author":"Schwartz","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"185101","DOI":"10.1088\/0957-4484\/27\/18\/185101","article-title":"TRAIL-coated lipid nanoparticles overcome resistance to soluble recombinant TRAIL in nan-small cell lung cancer cells","volume":"27","author":"Miguel","year":"2016","journal-title":"Nanotechnology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1021\/mp800136v","article-title":"Novel Cationic Lipid That Delivers siRNA and Enhances Therapeutic Effect in Lung Cancer Cells","volume":"6","author":"Chen","year":"2009","journal-title":"Mol. Pharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"109225","DOI":"10.1016\/j.biopha.2019.109225","article-title":"Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin","volume":"118","author":"Guo","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"074005","DOI":"10.1088\/2053-1591\/ab187a","article-title":"Methylene blue loaded, silica coated cobalt ferrite nanoparticles with potential for combination therapy","volume":"6","author":"Gandhi","year":"2019","journal-title":"Mater. Res. Express"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijbiomac.2018.10.005","article-title":"Doxorubicin-loaded casein nanoparticles for drug delivery: Preparation, characterization and in vitro evaluation","volume":"121","author":"Gandhi","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.2147\/DDDT.S246574","article-title":"Combination Chemotherapy of lung cancer -co delivery of Docetaxel Prodrug and Cisplatin using Aptomer-Decorated Lipid-Polymer Hybrid Nanoparticles","volume":"14","author":"Wu","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1166\/jnn.2011.3928","article-title":"Nanomedicine-Nanoemulsion formulation improves safety and efficacy of the anti-cancer drug paclitaxel according to preclinical assessment","volume":"11","author":"Lee","year":"2011","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systematic therapy for locally advanced and metastatic non-small cell lung cancer A review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Jain, K.K. (2020). Drug Delivery Systems, Methods in Molecular Biology, Springer.","DOI":"10.1007\/978-1-4939-9798-5"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/bs.acr.2017.11.003","article-title":"Chapter Five-Recent Advances in Nanoparticle-based cancer drug and gene delivery","volume":"137","author":"Amreddy","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"ref_14","first-page":"0032","article-title":"Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles","volume":"34","author":"Alavi","year":"2019","journal-title":"Drug Metab. Pers. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Subhan, M.A., Yalamarty, S.S.K., Filipczak, N., Parveen, F., and Torchilin, V.P. (2021). Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. J. Pers. Med., 11.","DOI":"10.3390\/jpm11060571"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.nano.2009.07.001","article-title":"Nanodelivery in airway diseases: Challenges and therapeutic applications","volume":"6","author":"Roy","year":"2010","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/1568009618666180525083451","article-title":"Inhaled micro\/nanoparticulate anticancer drug formulations: An emerging targeted drug delivery strategy for lung cancers","volume":"19","author":"Islam","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_18","unstructured":"El-Sherbiny, I.M., Villanueva, D.G., Herrera, D., and Smyth, H.D. (2011). Controlled Pulmonary Drug Delivery, Springer."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/211090a0","article-title":"Deposition of inhaled particles in human lungs","volume":"211","author":"Davies","year":"1966","journal-title":"Nature"},{"key":"ref_20","first-page":"16","article-title":"Pulmonary drug delivery systems\u2014An overview","volume":"1","author":"Thulasiramaraju","year":"2013","journal-title":"Asian J. Res. Pharm. Sci. Biotechnol."},{"key":"ref_21","first-page":"1","article-title":"Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases","volume":"3","author":"Smola","year":"2008","journal-title":"Int. J. Nanomed."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1073\/pnas.0600997103","article-title":"Role of target geometry in phagocytosis","volume":"103","author":"Champion","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-3659(97)00149-1","article-title":"Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: The effect of 1, 2-dipalmitoylphosphatidylcholine","volume":"51","author":"Evora","year":"1998","journal-title":"J. Control. Release"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.nano.2015.01.007","article-title":"Inhalable nanoparticulate powders for respiratory delivery","volume":"11","author":"Muralidharan","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/rmed.2001.1276","article-title":"Evolution of dry powder inhaler design, formulation, and performance","volume":"96","author":"Newman","year":"2002","journal-title":"Respir. Med."},{"key":"ref_27","unstructured":"(2023, March 10). Available online: https:\/\/my.clevelandclinic.org\/health\/drugs\/8694-inhalers."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.3109\/10717544.2015.1114047","article-title":"Loco-Regional Administration of Nanomedicines for the Treatment of Lung Cancer","volume":"23","author":"Lawson","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/jamp.2018.1508","article-title":"Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs","volume":"32","author":"Longest","year":"2019","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary Drug Delivery. Part I: Physiological Factors Affecting Therapeutic Effectiveness of Aerosolized Medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4155\/tde.13.71","article-title":"Liposomal Formulations for Inhalation","volume":"4","author":"Cipolla","year":"2013","journal-title":"Ther. Deliv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijpharm.2016.10.019","article-title":"Development of Controlled-Release Cisplatin Dry Powders for Inhalation against Lung Cancers","volume":"515","author":"Levet","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.apsb.2016.03.011","article-title":"Influence of Physical Properties of Carrier on the Performance of Dry Powder Inhalers","volume":"6","author":"Peng","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.03.006","article-title":"Emerging Inhalation Aerosol Devices and Strategies: Where Are We Headed?","volume":"75","author":"Zhou","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Abdulbaqi, I.M., Assi, R.A., Yaghmur, A., Darwis, Y., Mohtar, N., Parumasivam, T., Saqallah, F.G., and Wahab, H.A. (2021). Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080725"},{"key":"ref_36","first-page":"4981","article-title":"Nanotechnology-based drug delivery systems for the treatment of Alzheimer\u2019s disease","volume":"10","author":"Chorilli","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1705328","DOI":"10.1002\/adma.201705328","article-title":"Advances in biomaterials for drug delivery","volume":"30","author":"Fenton","year":"2018","journal-title":"Adv. Mater."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles from Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Liu, P., Chen, G., and Zhang, J. (2022). A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products Regulatory Environments, and Future Perspectives. Molecules, 27.","DOI":"10.3390\/molecules27041372"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Namiot, E.D., Sokolov, A.V., Chubarev, V.N., Tarasov, V.V., and Schioth, H.B. (2023). Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals, and Use for COVID-19 Vaccines. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010787"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sarfraz, M., Afzal, A., Yang, T., Gai, Y., Raza, S.M., Khan, M.W., Cheng, Y., Ma, X., and Xiang, G. (2018). Development of dual drug loaded nanosized liposomal formulation by a reengineered ethanolic injection method and its pre-clinical pharmacokinetic studies. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10030151"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s13346-018-0587-4","article-title":"Rapid optimization of liposome characteristics using a combined microfluidics and design-of-experiment approach","volume":"9","author":"Sedighi","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Trucillo, P., Campardelli, R., and Reverchon, E. (2020). Liposomes: From Bangham to Supercritical Fluids. Processes, 8.","DOI":"10.3390\/pr8091022"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"061001","DOI":"10.1088\/1478-3975\/aac7a2","article-title":"Engineering Approaches of Smart, Bio-Inspired Vesicles for Biomedical Applications","volume":"15","author":"Abraham","year":"2018","journal-title":"Phys. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"104984","DOI":"10.1016\/j.supflu.2020.104984","article-title":"Sustainable Technologies for Liposome Preparation","volume":"165","author":"Maja","year":"2020","journal-title":"J. Supercrit. Fluids"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Gbian, D.L., and Omri, A. (2022). Lipid-based drug delivery systems for Diseases Management. Biomedicines, 12.","DOI":"10.3390\/biomedicines10092137"},{"key":"ref_49","first-page":"795","article-title":"Nanoscale drug delivery systems and the blood\u2013brain barrier","volume":"9","author":"Alyautdin","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1021\/acs.jpcb.5b02891","article-title":"Microfluidic mixing: A general method for encapsulating macromolecules in lipid nanoparticles","volume":"119","author":"Leung","year":"2015","journal-title":"J. Phys. Chem. B"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","article-title":"Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases","volume":"264","author":"Tapeinos","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/17425247.2018.1504018","article-title":"Solid Lipid Nanoparticles in Drug Delivery: Characterization and design","volume":"15","author":"Mu","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.scp.2017.07.002","article-title":"Lipid nanoparticles:Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery","volume":"6","author":"Ganesan","year":"2017","journal-title":"Sustain. Chem. Pharm."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Filipczak, N., Yalamarty SS, K., Li, X., Khan, M.M., Parveen, F., and Torchilin, V. (2021). Lipid-Based Drug Delivery Systems in Regenerative Medicine. Materials, 14.","DOI":"10.3390\/ma14185371"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jps.23830","article-title":"Design of Lipid Matrix Particles for Fenofibrate: Effect of Polymorphism of Glycerol Monostearate on Drug Incorporation and Release","volume":"103","author":"Xia","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1021\/mp300452g","article-title":"Formation of Stable Nanocarriers by in Situ Ion Pairing during Block-Copolymer-Directed Rapid Precipitation","volume":"10","author":"Pinkerton","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s11095-006-9033-2","article-title":"Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN)","volume":"23","author":"Li","year":"2006","journal-title":"Pharm. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12951-019-0514-y","article-title":"Nano-drug delivery systems in wound treatment and skin regeneration","volume":"17","author":"Wang","year":"2019","journal-title":"J. Nanobiotechnol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"118484","DOI":"10.1016\/j.ijpharm.2019.118484","article-title":"Preclinical safety of topically administered nanostructured lipid carriers (NLC) for wound healing application: Biodistribution and toxicity studies","volume":"569","author":"Vairo","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"25683","DOI":"10.18632\/oncotarget.8361","article-title":"Grapefruit-derived nanovectors deliver miR-18a for treatment of liver metastasis of colon cancer by induction of M1 macrophages","volume":"7","author":"Teng","year":"2016","journal-title":"Oncotarget"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/ncomms2886","article-title":"Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids","volume":"4","author":"Wang","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.biomaterials.2016.06.018","article-title":"Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer","volume":"101","author":"Zhang","year":"2016","journal-title":"Biomaterials"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/mt.2016.159","article-title":"Edible Ginger-derived Nano-lipids Loaded with Doxorubicin as a Novel Drug-delivery Approach for Colon Cancer Therapy","volume":"24","author":"Zhang","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_65","first-page":"2051","article-title":"Enhancing the anti-colon cancer activity of quercetin by self-assembled micelles","volume":"10","author":"Xu","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2147\/IJN.S232777","article-title":"Tumor targeted curcumin delivery by folate-modified MPEG-PCL self-assembly micelles for colorectal cancer therapy","volume":"15","author":"Hu","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat. Mater."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1021\/la047590p","article-title":"Cubicphasenanoparticles (Cubosome): Principlesfor controlling size, structure, and stability","volume":"21","author":"Barauskas","year":"2005","journal-title":"Langmuir ACS J. Surf. Colloids"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"16647","DOI":"10.1021\/la302721n","article-title":"Earliest stage of the tetrahedral nanochannel formation in cubosome particles from unilamellar nanovesicles","volume":"28","author":"Angelov","year":"2012","journal-title":"Langmuir ACS J. Surf. Colloids"},{"key":"ref_70","first-page":"13321","article-title":"Cubosometopologiesatvariousparticlesizesandcrystallographicsymmetries","volume":"31","author":"Gozdz","year":"2015","journal-title":"Langmuir ACS J. Surf. Colloids"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1248\/cpb.c19-00370","article-title":"Novel cubosome system resistant to lipid removal by serum albumin","volume":"67","author":"Uyama","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"ref_72","first-page":"13","article-title":"Elimination of established tumors with nanodisc-based combination chemoimmunotherapy","volume":"4","author":"Kuai","year":"2017","journal-title":"Sci. Adv."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Saber, M.M., Al-Mahallawi, A.M., Nassar, N.N., Stork, B., and Shouman, S.A. (2018). Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4727-5"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13578-019-0282-2","article-title":"Exosomes: Biogenesis, Biologic Function and Clinical Potential","volume":"9","author":"Zhang","year":"2019","journal-title":"Cell Biosci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e1523","DOI":"10.1002\/wnan.1523","article-title":"Outer membrane vescicles for vaccination and targeed drug delivery","volume":"11","author":"Wang","year":"2019","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/acsomega.2c04078","article-title":"Advances in Lung Cancer Treatment Using Nanomedicines","volume":"8","author":"Sharma","year":"2023","journal-title":"ACS Omega"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3109\/10717544.2013.863526","article-title":"Development and Evaluation of a Dry Powder Formulation of Liposome-Encapsulated Oseltamivir Phosphate for Inhalation","volume":"22","author":"Tang","year":"2015","journal-title":"Drug Deliv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.apsb.2018.03.004","article-title":"Inhalation Treatment of Primary Lung Cancer Using Liposomal Curcumin Dry Powder Inhalers","volume":"8","author":"Zhang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1016\/j.xphs.2019.05.009","article-title":"Formulation and Characterization of Spray-Dried Powders Containing Vincristine-Liposomes for Pulmonary Delivery and Its Pharmacokinetic Evaluation From In Vitro and In Vivo","volume":"108","author":"Xu","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1749-6632.2000.tb07033.x","article-title":"9-Nitrocamptothecin Liposome Aerosol Treatment of Human Cancer Subcutaneous Xenografts and Pulmonary Cancer Metastases in Mice","volume":"922","author":"Knight","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s002800050966","article-title":"Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice","volume":"44","author":"Koshkina","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Parvathaneni, V., Kulkarni, N.S., Shukla, S.K., Farrales, P.T., Kunda, N.K., Muth, A., and Gupta, V. (2020). Systematic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030206"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"102320","DOI":"10.1016\/j.nano.2020.102320","article-title":"Synergistic Co-Loading of Vincristine Improved Chemotherapeutic Potential of Pegylated Liposomal Doxorubicin against Triple Negative Breast Cancer and Non-Small Cell Lung Cancer","volume":"31","author":"Ghosh","year":"2021","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_84","first-page":"3258","article-title":"Paclitaxel Liposome Aerosol Treatment Induces Inhibition of Pulmonary Metastases in Murine Renal Carcinoma Model","volume":"7","author":"Koshkina","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.2147\/IJN.S306831","article-title":"Design and Characterization of Spray-Dried Proliposomes for the Pulmonary Delivery of Curcumin","volume":"16","author":"Adel","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1089\/jamp.2011.0928","article-title":"Targeted Delivery of Transferrin- Conjugated Liposomes to an Orthotopic Model of Lung Cancer in Nude Rats","volume":"25","author":"Gaspar","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"119177","DOI":"10.1016\/j.ijpharm.2020.119177","article-title":"Paclitaxel-in-Liposome-in-Bacteria for Inhalation Treatment of Primary Lung Cancer","volume":"578","author":"Zhang","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2010.02.014","article-title":"A Toxicological Evaluation of Inhaled Solid Lipid Nanoparticles Used as a Potential Drug Delivery System for the Lung","volume":"75","author":"Nassimi","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1080\/03639045.2017.1310223","article-title":"Microparticles Containing Erlotinib-Loaded Solid Lipid Nanoparticles for Treatment of Non-Small Cell Lung Cancer","volume":"43","author":"Bakhtiary","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11095-020-02794-z","article-title":"Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles","volume":"37","author":"Nafee","year":"2020","journal-title":"Pharm. Res."},{"key":"ref_91","first-page":"1912","article-title":"Development, Optimization and Evaluation of Surfactant-Based Pulmonary Nanolipid Carrier System of Paclitaxel for the Management of Drug Resistance Lung Cancer Using Box-Behnken Design","volume":"23","author":"Kaur","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s11095-013-0984-9","article-title":"Efficacy of Aerosolized Celecoxib Encapsulated Nanostructured Lipid Carrier in Non-Small Cell Lung Cancer in Combination with Docetaxel","volume":"30","author":"Patel","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"121046","DOI":"10.1016\/j.ijpharm.2021.121046","article-title":"Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC)","volume":"607","author":"Patil","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3121\/cmr.4.3.218","article-title":"Gene therapy for cancer treatment: Past, present, and future","volume":"4","author":"Cross","year":"2006","journal-title":"Clin. Med. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","article-title":"Entering the modern era of gene therapy","volume":"70","author":"Anguela","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.semcancer.2019.10.020","article-title":"Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges","volume":"69","author":"Mirza","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/gt.2017.41","article-title":"Engineering liposomal nanoparticles for targeted gene therapy","volume":"24","author":"Zylberberg","year":"2017","journal-title":"Gene Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/5584_2019_463","article-title":"The horizon of gene therapy in modern medicine: Advances and challenges","volume":"1247","author":"Arjmand","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejpb.2007.07.011","article-title":"Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells","volume":"68","author":"Choi","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1089\/jamp.2017.1364","article-title":"Hybrid Lipid\/Polymer Nanoparticles for Pulmonary Delivery of SiRNA: Development and Fate upon in Vitro Deposition on the Human Epithelial Airway Barrier","volume":"31","author":"Costabile","year":"2018","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.7150\/thno.39816","article-title":"Strategy to Enhance Lung Cancer Treatment by Five Essential Elements: Inhalation Delivery, Nanotechnology, Tumor-Receptor Targeting, Chemo- and Gene Therapy","volume":"9","author":"Garbuzenko","year":"2019","journal-title":"Theranostics"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"14792","DOI":"10.1021\/acsnano.2c05647","article-title":"Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation","volume":"16","author":"Kim","year":"2022","journal-title":"ACS Nano"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"102903","DOI":"10.1016\/j.jddst.2021.102903","article-title":"Systematic development and characterization of inhalable dry powder containing Polymeric Lipid Hybrid Nanocarriers co-loaded with ABCB1 shRNA and docetaxel using QbD approach","volume":"66","author":"Bardoliwala","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/jps.20591","article-title":"Development of a Respirable, Sustained Release Microcarrier for 5-Fluorouracil I: In Vitro Assessment of Liposomes, Microspheres, and Lipid Coated Nanoparticles","volume":"95","author":"Hitzman","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1007\/s11095-022-03392-x","article-title":"Inhaled Indomethacin-Loaded Liposomes as Potential Therapeutics against Non-Small Cell Lung Cancer (NSCLC)","volume":"39","author":"Sarvepalli","year":"2022","journal-title":"Pharm. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1007\/s13346-021-01088-0","article-title":"Pulmonary Delivery of Osimertinib Liposomes for Non-Small Cell Lung Cancer Treatment: Formulation Development and in vitro Evaluation","volume":"12","author":"Sawant","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/17425247.2022.2076833","article-title":"Simultaneous Pulmonary Administration of Celecoxib and Naringin Using a Nebulization-Friendly Nanoemulsion: A Device-Targeted Delivery for Treatment of Lung Cancer","volume":"19","author":"Nasr","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s13346-018-0526-4","article-title":"Excipient Selection and Aerodynamic Characterization of Nebulized Lipid-Based Nanoemulsion Loaded with Docetaxel for Lung Cancer Treatment","volume":"9","author":"Asmawi","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Chauhan, G., Wang, X., Yousry, C., and Gupta, V. (2023). Scalable Production and In Vitro Efficacy of Inhaled Erlotinib Nanoemulsion for Enhanced Efficacy in Non-Small Cell Lung Cancer (NSCLC). Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030996"},{"key":"ref_111","first-page":"585","article-title":"WenDing Preparation and Characterization of Solid Lipid Nanoparticles Loaded with Epirubicin for Pulmonary Delivery","volume":"65","author":"Hu","year":"2010","journal-title":"Pharmazie"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1080\/10717544.2022.2086938","article-title":"Anti-Lung Cancer Effect of Paclitaxel Solid Lipid Nanoparticles Delivery System with Curcumin as Co-Loading Partner in Vitro and in Vivo","volume":"29","author":"Pi","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-5173(00)00378-1","article-title":"Characterisation of a Novel Solid Lipid Nanoparticle Carrier System Based on Binary Mixtures of Liquid and Solid Lipids","volume":"199","author":"Jenning","year":"2000","journal-title":"Int. J. Pharm."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"101502","DOI":"10.1016\/j.jddst.2020.101502","article-title":"Inhalable spray dried lipid nanoparticles for the co-delivery of paclitaxel and doxorubicin in lung cancer","volume":"56","author":"Kaur","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcis.2014.12.092","article-title":"Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: In vitro and in vivo studies","volume":"445","author":"Jyoti","year":"2015","journal-title":"J. Colloid Interface Sci."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Majumder, J., and Minko, T. (2021). Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071063"},{"key":"ref_117","first-page":"149","article-title":"A Review of Chemotherapy and Photodynamic Therapy for Lung Cancer Treatment","volume":"21","author":"Manoto","year":"2021","journal-title":"Anticancer. Agents Med. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-Line Immunotherapy for Non-Small-Cell Lung Cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"120504","DOI":"10.1016\/j.ijpharm.2021.120504","article-title":"Encapsulation of a CpG nucleotide in cationic liposomes enhances its local antitumor activity following pulmonary delivery in a murine model of metastatic lung cancer","volume":"600","author":"Vanvarenberg","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"120572","DOI":"10.1016\/j.ijpharm.2021.120572","article-title":"Pulmonary Delivery of Cationic Liposomal Hydroxycamptothecin and 5-Aminolevulinic Acid for Chemo-Sonodynamic Therapy of Metastatic Lung Cancer","volume":"601","author":"Xiao","year":"2021","journal-title":"Int. J. Pharm."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/5\/1457\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:32:23Z","timestamp":1760124743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/5\/1457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":120,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["pharmaceutics15051457"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15051457","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}